Loading
A phase 1/2 trial of Belzutifan, Palbociclib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) is a phase 1/2 interventional study registered as NCT05468697 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2022-08-10 and due to reach its primary completion in 2026-10-22. Interventions recorded: Belzutifan, Palbociclib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Belzutifan, Renal cell carcinoma, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/